Addex Therapeutics (ADXN.SW) Osake Kurssi

Addex Therapeutics Ltd is primarily active in the pharmaceutical industry.

The main competitors of Addex Therapeutics Ltd in the market are other biopharmaceutical companies involved in the development and commercialization of novel therapies and treatments targeting similar disease areas. Some key competitors include AbbVie Inc., Alkermes plc, Eli Lilly and Company, and Johnson & Johnson.

Addex Therapeutics Ltd is a biopharmaceutical company with a rich history and background in the field of neuroscience. Founded in 2002, Addex has constantly been working towards the development of innovative therapeutic solutions for diseases such as Parkinson's and Schizophrenia. The company has a strong focus on modulating specific receptors in the brain to target and treat these conditions. With a dedicated team of scientists and researchers, Addex Therapeutics has made significant advancements in drug discovery and has several promising compounds in its pipeline. The company's commitment to improving the lives of patients and its relentless pursuit of groundbreaking therapies has positioned Addex as a leading player in the biopharmaceutical industry.

Addex Therapeutics Ltd has achieved significant milestones in its industry. The company successfully developed and advanced its allosteric modulator drugs, targeting various diseases such as Parkinson's disease and schizophrenia. Addex Therapeutics also achieved notable progress in its clinical development programs, conducting successful Phase II trials for its lead candidate, dipraglurant, in Parkinson's disease levodopa-induced dyskinesia. The company has further strengthened its position through collaborations with industry-leading partners to expedite the development and commercialization of its innovative therapies. With its commitment to scientific excellence and strong pipeline, Addex Therapeutics Ltd continues to make remarkable strides in the field of allosteric modulation for the benefit of patients and investors.

Addex Therapeutics Ltd is primarily present in multiple countries and regions worldwide. The company has a global presence with a focus on key markets such as the United States, Europe, and Asia. By expanding its reach across these regions, Addex Therapeutics Ltd aims to maximize its market potential and cater to a diverse range of customers. With its presence in multiple countries and regions, Addex Therapeutics Ltd is well-positioned to capitalize on emerging opportunities and strengthen its position as a leading player in the pharmaceutical industry.

Addex Therapeutics Ltd represents a set of core values and a corporate philosophy that guide its operations. The company is committed to scientific excellence, innovation, and patient-centricity in the field of drug discovery and development. Addex Therapeutics strives to improve the lives of patients by developing novel oral small molecules targeting specific biological pathways. With a focus on therapeutic areas such as neurology and immunology, the company aims to deliver innovative solutions to unmet medical needs. By fostering collaboration and leveraging its expertise, Addex Therapeutics is dedicated to advancing the frontiers of medicine and bringing transformative therapies to patients worldwide.

9 analyytikkoa arvioi tällä hetkellä Addex Therapeutics-osaketta: 0 suosittaa ostoa, 2 pitoa ja 7 myyntiä. Vuodelle 2026 analyytikot odottavat Addex Therapeutics-yhtiöltä 1,50 M CHF liikevaihtoa ja −0,03 CHF osakekohtaista tulosta.

Addex Therapeutics Analyytikkojen kursstavoitteet 2026

Nykyisellä valuuttakurssilla Addex Therapeutics-osake noteerataan hintaan 0,02 EUR (0,02 CHF).

Addex Therapeutics-osake (ADXN.SW) on listattuna 4 pörssissä, muun muassa: London (0QNV.L), SIX (Zürich) (ADXN.SW), Frankfurt (APE.F), München (APE.MU).

Addex Therapeutics Ltd is a biopharmaceutical company specialized in the development of novel orally available drugs for the treatment of central nervous system diseases, as well as inflammatory and metabolic diseases. The company has developed a unique drug design and screening platform system focusing on allosteric modulators to selectively and effectively develop drugs. Addex Therapeutics operates in three main areas: clinical development programs, preclinical development programs, and partnerships with third parties. In the clinical development programs, Addex Therapeutics has various drug candidates in clinical development or near the start of clinical trials. The company works closely with contract research organizations to conduct these studies and ensure the safety and efficacy of the drug candidates. Addex Therapeutics' clinical development programs include the following drug classes: - ADX10059: A calcium channel modulator that offers an alternative therapy for the treatment of chronic migraine and gastroesophageal reflux disease. - ADX71149: A GABAB receptor modulator that represents a potential treatment option for schizophrenia and alcoholism. - ADX71441: A G-protein coupled receptor modulator that represents a potential treatment option for anxiety disorders. In the preclinical development programs, Addex Therapeutics is working on the development of drug candidates in the earliest phase of the development process. These drug candidates are still in early research and are being tested in vitro and in vivo to determine their potential for further development in later research stages, considering safety and efficacy. Addex Therapeutics has a wide range of technologies for drug discovery. The company utilizes various technologies to effectively shape drug design. Allosteric modulation is at the core of Addex Therapeutics' drug design system, allowing the company to selectively target specific targets within cells and tissues that play a role in various diseases. In partnerships with third parties, Addex Therapeutics collaborates with other companies or academic partners to further develop its drug candidates or develop new technologies. Addex Therapeutics has signed several agreements with leading biotech and pharmaceutical companies to expand the use of allosteric modulators. In addition to its drug candidates, Addex Therapeutics also offers drug discovery services. The company provides its customers with access to its technology platform to identify new drug candidates and accelerate drug development. These services are an important part of Addex Therapeutics' business model and contribute to the company's growth and diversification. Overall, Addex Therapeutics has a unique business model based on the development of novel drugs targeting specific targets within cells and tissues. With its technology platform and broad expertise in drug development, the company is able to efficiently and effectively navigate its drug candidates through clinical development. Addex Therapeutics' strategic partnerships and drug discovery services provide additional growth opportunities. Translation provided by a language model trained on a mixture of professional translations and publicly available data.

odotettu liikevaihto Addex Therapeutics on 1,50 M CHF. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Addex Therapeutics on −3,92 M CHF. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Addex Therapeutics:n hinta-voitto-suhde (P/E) on tällä hetkellä −0,76. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Addex Therapeutics-osakkeen arvostusta.

Addex Therapeutics:n hinta-myynti-suhde (P/S) on tällä hetkellä 1,98. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Addex Therapeutics-osakkeen arvostuskennuslukuna.

Addex Therapeutics:n Eulpool-laatuscore on 3/10.

Addex Therapeutics:n ISIN on CH0029850754. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Addex Therapeutics:n WKN on A0MSH6. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Addex Therapeutics:n ticker on ADXN.SW. Tämä pörssinoteeraus käytetään Addex Therapeutics-osakkeiden kauppaan pörssissä.